Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC(50)] = 354 nM) and in human fetal hepatocytes infected with genotyp...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Perni, Robert B., Almquist, Susan J., Byrn, Randal A., Chandorkar, Gurudatt, Chaturvedi, Pravin R., Courtney, Lawrence F., Decker, Caroline J., Dinehart, Kirk, Gates, Cynthia A., Harbeson, Scott L., Heiser, Angela, Kalkeri, Gururaj, Kolaczkowski, Elaine, Lin, Kai, Luong, Yu-Ping, Rao, B. Govinda, Taylor, William P., Thomson, John A., Tung, Roger D., Wei, Yunyi, Kwong, Ann D., Lin, Chao
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2006
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1426435/
https://ncbi.nlm.nih.gov/pubmed/16495249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.50.3.899-909.2006
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires